31.73
-0.66(-2.04%)
Currency In USD
| Previous Close | 32.39 |
| Open | 31.83 |
| Day High | 32.09 |
| Day Low | 29.25 |
| 52-Week High | 54.3 |
| 52-Week Low | 1.72 |
| Volume | 17,166 |
| Average Volume | 23,682 |
| Market Cap | 194.04M |
| PE | -7.97 |
| EPS | -3.98 |
| Moving Average 50 Days | 37.77 |
| Moving Average 200 Days | 24.61 |
| Change | -0.66 |
If you invested $1000 in Monopar Therapeutics Inc. (MNPR) since IPO date, it would be worth $239.47 as of June 01, 2025 at a share price of $31.73. Whereas If you bought $1000 worth of Monopar Therapeutics Inc. (MNPR) shares 5 years ago, it would be worth $820.96 as of June 01, 2025 at a share price of $31.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
GlobeNewswire Inc.
May 13, 2025 12:00 PM GMT
WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
GlobeNewswire Inc.
May 07, 2025 6:30 AM GMT
WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
GlobeNewswire Inc.
Apr 29, 2025 12:00 PM GMT
WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on